{"name":"Vertex Pharmaceuticals Incorporated","slug":"vertex-pharmaceuticals-incorporated","ticker":"","exchange":"","domain":"vertexincorporated.com","description":"","hq":"Boston","founded":0,"employees":"","ceo":"Reshma Kewalramani","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":27,"colorKey":"oncology","drugs":[{"name":"14C-VX-993","genericName":"14C-VX-993","slug":"14c-vx-993","indication":"Other","status":"phase_1"},{"name":"IVA","genericName":"IVA","slug":"iva","indication":"Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D)","status":"marketed"},{"name":"Ivacaftor Exposed","genericName":"Ivacaftor Exposed","slug":"ivacaftor-exposed","indication":"Cystic fibrosis","status":"phase_2"},{"name":"LUM","genericName":"LUM","slug":"lum","indication":"Short bowel syndrome (SBS)","status":"marketed"},{"name":"Placebo matched to VX-661/ ivacaftor","genericName":"Placebo matched to VX-661/ ivacaftor","slug":"placebo-matched-to-vx-661-ivacaftor","indication":"Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators","status":"phase_3"},{"name":"TEZ/IVA","genericName":"TEZ/IVA","slug":"tez-iva","indication":"Cystic fibrosis in patients with one or two F508del mutations","status":"phase_3"},{"name":"VX-661 plus ivacaftor combination","genericName":"VX-661 plus ivacaftor combination","slug":"vx-661-plus-ivacaftor-combination","indication":"Cystic fibrosis in patients with one or two copies of the F508del mutation","status":"phase_3"},{"name":"VX-828","genericName":"VX-828","slug":"vx-828","indication":"Other","status":"phase_1"},{"name":"VX-880","genericName":"VX-880","slug":"vx-880","indication":"Treatment of advanced retinitis pigmentosa","status":"phase_3"},{"name":"AVN-944 capsules for oral administration","genericName":"AVN-944 capsules for oral administration","slug":"avn-944-capsules-for-oral-administration","indication":"Other","status":"phase_1"},{"name":"Cethrin","genericName":"Cethrin","slug":"cethrin","indication":"Other","status":"phase_1"},{"name":"ELX/TEZ/IVA","genericName":"ELX/TEZ/IVA","slug":"elx-tez-iva","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation","status":"phase_3"},{"name":"Immunosuppressant Regimen","genericName":"Immunosuppressant Regimen","slug":"immunosuppressant-regimen","indication":"Other","status":"marketed"},{"name":"LUM/IVA","genericName":"LUM/IVA","slug":"lum-iva","indication":"Cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del-CFTR mutation or heterozygous for the F508del-CFTR mutation and one residual function mutation","status":"marketed"},{"name":"Placebo (matched to HB/APAP)","genericName":"Placebo (matched to HB/APAP)","slug":"placebo-matched-to-hb-apap","indication":"Control arm in Phase 3 clinical trial (indication under investigation for HB/APAP comparator)","status":"phase_3"},{"name":"Placebo (matched to IVA)","genericName":"Placebo (matched to IVA)","slug":"placebo-matched-to-iva","indication":"Control comparator in phase 3 clinical trial for IVA (specific indication unknown)","status":"phase_3"},{"name":"Placebo (matched to SUZ)","genericName":"Placebo (matched to SUZ)","slug":"placebo-matched-to-suz","indication":"Other","status":"phase_3"},{"name":"Placebo (matched to ivacaftor)","genericName":"Placebo (matched to ivacaftor)","slug":"placebo-matched-to-ivacaftor","indication":"Matched to ivacaftor in clinical trials","status":"phase_3"},{"name":"SUZ","genericName":"SUZ","slug":"suz","indication":"Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation","status":"marketed"},{"name":"TEZ","genericName":"TEZ","slug":"tez","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor)","status":"marketed"},{"name":"Tezacaftor/Ivacaftor","genericName":"Tezacaftor/Ivacaftor","slug":"tezacaftor-ivacaftor","indication":"Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation","status":"phase_3"},{"name":"VNZ/TEZ/D-IVA","genericName":"VNZ/TEZ/D-IVA","slug":"vnz-tez-d-iva","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-121/TEZ/D-IVA","genericName":"VX-121/TEZ/D-IVA","slug":"vx-121-tez-d-iva","indication":"Cystic fibrosis in patients with one or two Phe508del alleles","status":"phase_3"},{"name":"VX-445/TEZ/IVA","genericName":"VX-445/TEZ/IVA","slug":"vx-445-tez-iva","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-661/Ivacaftor","genericName":"VX-661/Ivacaftor","slug":"vx-661-ivacaftor","indication":"Cystic fibrosis","status":"phase_3"},{"name":"VX-770","genericName":"VX-770","slug":"vx-770","indication":"Cystic fibrosis with G551D-CFTR mutation","status":"phase_3"},{"name":"VX-809","genericName":"VX-809","slug":"vx-809","indication":"Cystic fibrosis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Pegylated Interferon Alfa 2a","genericName":"Pegylated Interferon Alfa 2a","slug":"pegylated-interferon-alfa-2a","indication":"Chronic hepatitis C","status":"marketed"},{"name":"CTX001","genericName":"CTX001","slug":"ctx001","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Ribavirin (Copegus®)","genericName":"Ribavirin (Copegus®)","slug":"ribavirin-copegus","indication":"Chronic hepatitis C virus (HCV) infection in combination with peginterferon alfa or direct-acting antivirals","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Exa-cel","genericName":"Exa-cel","slug":"exa-cel","indication":"Sickle cell disease","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"HB/APAP","genericName":"HB/APAP","slug":"hb-apap","indication":"Chronic hepatitis B infection","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Suzetrigine (SUZ)","genericName":"Suzetrigine (SUZ)","slug":"suzetrigine-suz","indication":"Acute pain (post-operative pain)","status":"marketed"}]}],"pipeline":[{"name":"14C-VX-993","genericName":"14C-VX-993","slug":"14c-vx-993","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IVA","genericName":"IVA","slug":"iva","phase":"marketed","mechanism":"IVA is a CFTR potentiator that increases the open probability of the cystic fibrosis transmembrane conductance regulator protein to enhance chloride ion transport.","indications":["Cystic fibrosis in patients aged 6 months and older with specific CFTR mutations (gating mutations including G551D)","Cystic fibrosis in combination with lumacaftor in patients with F508del-CFTR mutations"],"catalyst":""},{"name":"Ivacaftor Exposed","genericName":"Ivacaftor Exposed","slug":"ivacaftor-exposed","phase":"phase_2","mechanism":"Potentiates CFTR chloride channel function","indications":["Cystic fibrosis"],"catalyst":""},{"name":"LUM","genericName":"LUM","slug":"lum","phase":"marketed","mechanism":"LUM001 is a β-catenin modulator that enhances Wnt/β-catenin signaling to promote the expansion and function of intestinal stem cells and barrier function.","indications":["Short bowel syndrome (SBS)"],"catalyst":""},{"name":"Pegylated Interferon Alfa 2a","genericName":"Pegylated Interferon Alfa 2a","slug":"pegylated-interferon-alfa-2a","phase":"marketed","mechanism":"Pegylated Interferon Alfa 2a activates innate immune responses by binding to interferon-alpha receptors, enhancing antiviral and antiproliferative activity.","indications":["Chronic hepatitis C","Chronic hepatitis B","Certain malignancies (e.g., melanoma, follicular lymphoma)"],"catalyst":""},{"name":"Placebo matched to VX-661/ ivacaftor","genericName":"Placebo matched to VX-661/ ivacaftor","slug":"placebo-matched-to-vx-661-ivacaftor","phase":"phase_3","mechanism":"This is a placebo control arm in a clinical trial comparing VX-661 (a CFTR corrector) combined with ivacaftor (a CFTR potentiator) against placebo in cystic fibrosis patients.","indications":["Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulators"],"catalyst":""},{"name":"Ribavirin (Copegus®)","genericName":"Ribavirin (Copegus®)","slug":"ribavirin-copegus","phase":"marketed","mechanism":"Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate pools and viral polymerase activity.","indications":["Chronic hepatitis C virus (HCV) infection in combination with peginterferon alfa or direct-acting antivirals","Severe respiratory syncytial virus (RSV) infection in immunocompromised patients"],"catalyst":""},{"name":"TEZ/IVA","genericName":"TEZ/IVA","slug":"tez-iva","phase":"phase_3","mechanism":"TEZ/IVA is a combination of tezacaftor and ivacaftor, which work together to increase the function of the CFTR protein in the lungs.","indications":["Cystic fibrosis in patients with one or two F508del mutations"],"catalyst":""},{"name":"VX-661 plus ivacaftor combination","genericName":"VX-661 plus ivacaftor combination","slug":"vx-661-plus-ivacaftor-combination","phase":"phase_3","mechanism":"VX-661 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector, and ivacaftor is a CFTR potentiator.","indications":["Cystic fibrosis in patients with one or two copies of the F508del mutation"],"catalyst":""},{"name":"VX-828","genericName":"VX-828","slug":"vx-828","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VX-880","genericName":"VX-880","slug":"vx-880","phase":"phase_3","mechanism":"VX-880 is a stem cell therapy that aims to restore vision in patients with advanced retinitis pigmentosa.","indications":["Treatment of advanced retinitis pigmentosa"],"catalyst":""},{"name":"AVN-944 capsules for oral administration","genericName":"AVN-944 capsules for oral administration","slug":"avn-944-capsules-for-oral-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CTX001","genericName":"CTX001","slug":"ctx001","phase":"phase_3","mechanism":"CTX001 is a genetically modified T-cell therapy that enhances patient immune cells to recognize and destroy cancer cells expressing specific antigens.","indications":["Relapsed or refractory multiple myeloma","Relapsed or refractory acute lymphoblastic leukemia (ALL)"],"catalyst":""},{"name":"Cethrin","genericName":"Cethrin","slug":"cethrin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ELX/TEZ/IVA","genericName":"ELX/TEZ/IVA","slug":"elx-tez-iva","phase":"phase_3","mechanism":"ELX/TEZ/IVA is a triple combination of CFTR modulators that work together to restore function of the cystic fibrosis transmembrane conductance regulator protein.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del-CFTR mutation","Cystic fibrosis in patients with other CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"Exa-cel","genericName":"Exa-cel","slug":"exa-cel","phase":"phase_3","mechanism":"Exa-cel is an in vivo CRISPR gene-editing therapy that modifies the BCL11A gene to reactivate fetal hemoglobin production in patients with sickle cell disease or beta-thalassemia.","indications":["Sickle cell disease","Beta-thalassemia major"],"catalyst":""},{"name":"HB/APAP","genericName":"HB/APAP","slug":"hb-apap","phase":"phase_3","mechanism":"HB/APAP is a combination therapy that pairs a hepatitis B antigen with acetaminophen to modulate immune responses against hepatitis B infection.","indications":["Chronic hepatitis B infection"],"catalyst":""},{"name":"Immunosuppressant Regimen","genericName":"Immunosuppressant Regimen","slug":"immunosuppressant-regimen","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LUM/IVA","genericName":"LUM/IVA","slug":"lum-iva","phase":"marketed","mechanism":"LUM/IVA is a combination of lumacaftor (a CFTR corrector) and ivacaftor (a CFTR potentiator) that work together to improve the processing and function of defective cystic fibrosis transmembrane conductance regulator (CFTR) protein.","indications":["Cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del-CFTR mutation or heterozygous for the F508del-CFTR mutation and one residual function mutation"],"catalyst":""},{"name":"Placebo (matched to HB/APAP)","genericName":"Placebo (matched to HB/APAP)","slug":"placebo-matched-to-hb-apap","phase":"phase_3","mechanism":"A placebo control matched to the active comparator HB/APAP (hydrocodone bitartrate/acetaminophen) that contains no pharmacologically active ingredients.","indications":["Control arm in Phase 3 clinical trial (indication under investigation for HB/APAP comparator)"],"catalyst":""},{"name":"Placebo (matched to IVA)","genericName":"Placebo (matched to IVA)","slug":"placebo-matched-to-iva","phase":"phase_3","mechanism":"Placebo is an inert control substance with no active pharmacological mechanism.","indications":["Control comparator in phase 3 clinical trial for IVA (specific indication unknown)"],"catalyst":""},{"name":"Placebo (matched to SUZ)","genericName":"Placebo (matched to SUZ)","slug":"placebo-matched-to-suz","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo (matched to ivacaftor)","genericName":"Placebo (matched to ivacaftor)","slug":"placebo-matched-to-ivacaftor","phase":"phase_3","mechanism":"This drug has no therapeutic effect.","indications":["Matched to ivacaftor in clinical trials"],"catalyst":""},{"name":"SUZ","genericName":"SUZ","slug":"suz","phase":"marketed","mechanism":"SUZ is a CFTR potentiator that enhances the function of cystic fibrosis transmembrane conductance regulator protein to improve chloride transport in cystic fibrosis patients.","indications":["Cystic fibrosis in patients with specific CFTR mutations responsive to potentiation"],"catalyst":""},{"name":"Suzetrigine (SUZ)","genericName":"Suzetrigine (SUZ)","slug":"suzetrigine-suz","phase":"marketed","mechanism":"Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.","indications":["Acute pain (post-operative pain)"],"catalyst":""},{"name":"TEZ","genericName":"TEZ","slug":"tez","phase":"marketed","mechanism":"TEZ (tezacaftor) is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly and traffic to the cell surface.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation (in combination with ivacaftor)","Cystic fibrosis in patients with specific CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"Tezacaftor/Ivacaftor","genericName":"Tezacaftor/Ivacaftor","slug":"tezacaftor-ivacaftor","phase":"phase_3","mechanism":"Tezacaftor is a CFTR corrector that helps misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein fold correctly, while ivacaftor is a CFTR potentiator that increases the channel-opening probability of CFTR at the cell surface.","indications":["Cystic fibrosis in patients aged 6 years and older with at least one F508del mutation","Cystic fibrosis in patients with other CFTR mutations responsive to CFTR modulation"],"catalyst":""},{"name":"VNZ/TEZ/D-IVA","genericName":"VNZ/TEZ/D-IVA","slug":"vnz-tez-d-iva","phase":"phase_3","mechanism":"VNZ/TEZ/D-IVA is a triple combination therapy consisting of a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, a corrector, and a potentiator.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-121/TEZ/D-IVA","genericName":"VX-121/TEZ/D-IVA","slug":"vx-121-tez-d-iva","phase":"phase_3","mechanism":"VX-121/TEZ/D-IVA is a triple combination of a cystic fibrosis transmembrane conductance regulator (CFTR) corrector (VX-121), a CFTR potentiator (tezacaftor), and a CFTR amplifier (ivacaftor).","indications":["Cystic fibrosis in patients with one or two Phe508del alleles","Cystic fibrosis in patients with one F508del allele and one minimal function mutation"],"catalyst":""},{"name":"VX-445/TEZ/IVA","genericName":"VX-445/TEZ/IVA","slug":"vx-445-tez-iva","phase":"phase_3","mechanism":"VX-445/TEZ/IVA is a combination of three cystic fibrosis transmembrane conductance regulator (CFTR) modulators.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-661/Ivacaftor","genericName":"VX-661/Ivacaftor","slug":"vx-661-ivacaftor","phase":"phase_3","mechanism":"VX-661/Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"VX-770","genericName":"VX-770","slug":"vx-770","phase":"phase_3","mechanism":"VX-770 is a CFTR potentiator that increases the opening probability and duration of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the cell surface.","indications":["Cystic fibrosis with G551D-CFTR mutation","Cystic fibrosis with other gating mutations"],"catalyst":""},{"name":"VX-809","genericName":"VX-809","slug":"vx-809","phase":"phase_3","mechanism":"VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","indications":["Cystic fibrosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOandNS0RMRjdHUkEzNjZ0N0o4bVN1S2NHMFNpTExEcmR2UFp5bnFSbi1kQ1h1M0hGZzNuRDEwNGNadkZSVG9CS2taMWdteHBDVGJvMmtGVGpqelowZ1ZzRlhUeTBEaWtmekg0aHQyTkpTWEZfQUQ4MFlsQmhzN3JmTkppTVNma1RfTG83ZGNNRk5OeFBxYVF3a1pybzlNNExPSy1makQ4SHJBVlc2VkE4Z2J5NFBzOHZkV3pSZ0dBZzdhNzNuamc?oc=5","date":"2026-04-07","type":"deal","source":"Contract Pharma","summary":"Halozyme, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement - Contract Pharma","headline":"Halozyme, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5wWHU3c2hTVEdDRC1XcGtTUXpvUElCX0tMVHBaWXViRjBwTDYxSDRnNHM2Tnpod2hGN2Rza3NZcmJET2lPSVF0QnJoblRZSDIwRG1KNEtQMzZVcUN5UFpiYkhXWkdfTnpLMGJDUUxmZWRBUG05OFVOQXFlRllqZmc?oc=5","date":"2026-04-07","type":"pipeline","source":"Seeking Alpha","summary":"Vertex Pharma in pact with Halozyme for Hypercon (VRTX:NASDAQ) - Seeking Alpha","headline":"Vertex Pharma in pact with Halozyme for Hypercon (VRTX:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOR0JYbUdmdUtpa2EzQUpSRjZYcTAxZmNrSHUwczJCakU4d0ZBN0d3dm5PczJDNENsTzBVQzhmNWtUSmo1ZG1SOXFPTmhURkNCTFpzRXhNQnBaR2Qxd0RwUjN4ZE92TGF3bTdaN1pvN1J0UkZwVHBNOHRWblNpSk04TFBpdWNpRVAwbHdzeWJEY29oMlVtUlZyQUNxbVgyWFNQc2pRS2s4N0tSbUNDYjY4V2FKMjlkUDJsVzJkOW11TkVGckFY?oc=5","date":"2026-04-07","type":"deal","source":"AD HOC NEWS","summary":"Vertex Pharmaceuticals Inc stock: New Halozyme deal signals pipeline push - AD HOC NEWS","headline":"Vertex Pharmaceuticals Inc stock: New Halozyme deal signals pipeline push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOa09Zdm1QQnNVWVN3aXpCNEU4T3FRZmpmamxjTXUydWYyOVUxQXRld0tsdTRXcmZJY05qcTV6a0tjS0pPM0N4RXU1ZVlYbHYxSm0wNDVQeE16TV9iZXdBNF9US2pxc1dqOHdwUHBfZEdTcFgtWm1COGc1aFpmdHQ5ZEszUHpaMThUQWI3Y3RzdllsMXdCX2c?oc=5","date":"2026-04-01","type":"regulatory","source":"Seeking Alpha","summary":"Vertex Pharma wins FDA label expansion for cystic fibrosis therapies - Seeking Alpha","headline":"Vertex Pharma wins FDA label expansion for cystic fibrosis therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNX2R4WC1Oc2NiVDRRVURhNGVCblU0ZnMwMWFXVzdnVHo1UkdFWlZsQlgzamhSVHMtMTFMYWlYR0hqdXBhbWN2MlNRa1lYeldLSkZpdkI0SEc0TkZnd0VncVN6UExHR2FPVUJvOVBxeExOTG5qRnN0MnlfUS00UEJybGZ3emxhZw?oc=5","date":"2026-02-13","type":"pipeline","source":"Yahoo Finance","summary":"Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays - Yahoo Finance","headline":"Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdnJCQUh2RjJnRGNNdzlfNDVTSlZXSGthVWU2V2JFdkRRUXF6Y0M0aUh0aWU3NENFZXNONC1NTFJzZ3NtV2x1R3VtV25VaDJoWDN1VG56S1FvZTNNX2JFM0I0UGVPRXFoT1pEYWUwc1dUTGRUMXZuMWVlNlNxYl9xWGtIcEZyX2tNaHl2OVFJOUhPUS1iWlhCM0IzZlZGTTRWZ0xWblk3aVpFZGc?oc=5","date":"2026-01-31","type":"pipeline","source":"finviz.com","summary":"Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story - finviz.com","headline":"Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPNVNoeE5OWnBnUUtqbHZhMVVEWVdRYm1hazQzZzB3N0tsSVA4R1pxVkRIalZtT3JBQWVfWVFTVld6S2ZjWDB0RjVQZ3FDdnBDQkdoOGFvVk90RXRRekhMVW5JeHpmVFRQRnJzS28ydzJLX2VwMTlOblJEM3lzQnpaaXpKTS1LSE9CdnVyRV9JU1I3OXNTVEF2bzRhWVRPYV9UcG44cFozY3lCUFF3NFVZZ2pWXy1fZWsxSkxETGQzVjZ5MmI1OEltVFNEM1VETEpRQUd1ZnBPRlo1cTBC?oc=5","date":"2026-01-20","type":"earnings","source":"businesswire.com","summary":"Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - businesswire.com","headline":"Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQWE1GRVFTclBia2R1Wl9FV2poSHMzRTBENW1HcEU1QjdLbEtrNnVHN25XdHZjMWJnakR3cVBMRWk0UEludWp2UTRmRkhyeGtMS2xWSV8zSXpxSlJSam1HSE00bTExX00yMC1wMWlZc21HUlJPand3djQ4MmE4cEt5MlB3eXlFN1ptTUwzMXJid2NDZ1plcDVHSDJHU0dWenVZeUt0WU80dmswRGJxenJpTk8tWDRmNFNlSDJnSmFablpXSnRrNGdCa05SRUthTEVTeTlIT09jTGxYV0NPU3hPTU5yczd5SGd1MXlFVkJoaWdVOWtxM1dzMFB0NndYOG9sNFVLR2FOZ0gtQQ?oc=5","date":"2025-12-20","type":"trial","source":"TechStock²","summary":"Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch - TechStock²","headline":"Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNLXRXMENtZzAtQzY0b1UyMlQ5RC1RbzBJT2pGenVEZlZFRFV1T0hvdGZFcW82SnZiaWJDU3RyTk1MU3EyeXhOM3R1c3ktNjV0MVQ5LXU0ZFRzMXhLNFVDQnVDbkFBSDZiWk5xTGdiZUJnUjVDcUNEaUNUNkIwejE1a0JUdGxzcWxoTWRKRzdLUkt0aFNmc0JiR3NSSzVoTEFWRWRJ?oc=5","date":"2025-08-05","type":"trial","source":"BioSpace","summary":"Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings - BioSpace","headline":"Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNSjFhY0ExYzdrd1dJajVQa1lhT05SU25uSEZPeFJDREc2X3ZBUDhMcG9odVJuOVBCaUtUZXBqREFzanpyZUc0bWxFaVA0NlFyNGtJWEE2bERsY2FQZjJ3VHBlY193MnVwSDhtVy1tVm5JX3F0VDAxQmtYUWxobUYyNjI2QzVTTUFjalUtVE1FZU05cXhR?oc=5","date":"2025-07-15","type":"regulatory","source":"Yahoo Finance","summary":"EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Yahoo Finance","headline":"EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPa0dDMkt5bXhyYkF1YV80U3o2bkxWZUlKSm4zakJ1dVFzZzlsVkQzb0pPVktYUjRKZUlQR3pndHJ5WlV3LU9XT09GV0h3YjEyeGg0VHBBa0tidjRMYVRjcEVKZFdjQ2Y3ZEZZRnkyNEZkZUhLM05LYkpfRHpVVDl0X25TWWdZQXM0SDhvZ0ZMVXMyTDZ1cHZ3OEtLbE1GWllrR2ZzVGI1WEhYYUY5cVpjVE41Q011ZXRm?oc=5","date":"2025-04-15","type":"pipeline","source":"ArentFox Schiff","summary":"Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff","headline":"Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQNGhZSnljSUNJSGJ4SzNPVXdNeXNncWRyT1dUWVY2VDVxWDFhamJGQUtSWlhJLVVJMmhSQjROckJNemJGZVlkY3ZmR0ZmYXBiX1J1ZHExdk1ZOW1wTWp5T1ZWa283c2RkYjdkUlgwMEtNejlNb3NJbVZJZlpyVmNweWptQ3dWeDAtV0NfVEJXNG5RU1pTZFRUY01hOEd0SXdwMXFTdEpGTnJTMklMX2NRUnBwUGhndjcyWUJzc0pn?oc=5","date":"2025-01-30","type":"pipeline","source":"Vertex Pharmaceuticals Newsroom","summary":"(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Vertex Pharmaceuticals Newsroom","headline":"(suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain","sentiment":"neutral"}],"patents":[],"drugCount":33,"phaseCounts":{"phase_1":4,"marketed":9,"phase_2":1,"phase_3":19},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}